O Galm

Summary

Affiliation: RWTH Aachen
Country: Germany

Publications

  1. pmc Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer
    Erik Noetzel
    Molecular Oncology Group, Institute of Pathology, University Hospital of the RWTH Aachen, Aachen, Germany
    BMC Cancer 8:154. 2008
  2. pmc Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer
    Jason P W Carey
    Department of Biology, Center for Cancer Research and Therapeutics Development, Clark Atlanta University, Atlanta, GA 30314, USA
    BMC Cancer 9:173. 2009
  3. ncbi request reprint DNA methylation changes in multiple myeloma
    O Galm
    Medizinische Klinik IV, Universitaetsklinikum Aachen, 52074 Aachen, Germany
    Leukemia 18:1687-92. 2004
  4. ncbi request reprint Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia
    Oliver Galm
    Medizinische Klinik IV, Universitatsklinikum Aachen, Rheinisch Westfälische Technische Hochschule Aachen, Aachen, Germany
    Ann Hematol 84:39-46. 2005
  5. doi request reprint Epigenetic inactivation of secreted Frizzled-related proteins in acute myeloid leukaemia
    E Jost
    Medizinische Klinik IV, Universitaetsklinikum Aachen, RWTH Aachen, Aachen, Germany
    Br J Haematol 142:745-53. 2008
  6. doi request reprint Epigenetic dysregulation of secreted Frizzled-related proteins in multiple myeloma
    E Jost
    Medizinische Klinik IV, Universitaetsklinikum Aachen, RWTH Aachen, Germany
    Cancer Lett 281:24-31. 2009
  7. ncbi request reprint Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders
    E Jost
    Medizinische Klinik IV, Universitaetsklinikum Aachen, RWTH Aachen, Germany
    Leukemia 21:505-10. 2007
  8. ncbi request reprint Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis
    J Veeck
    Institute of Pathology, University Hospital of the RWTH Aachen, Aachen, Germany
    Oncogene 25:3479-88. 2006
  9. ncbi request reprint Heart and muscle involvement by extra-medullary myeloid leukemia: a case report and review of the literature
    E Jost
    Medizinische Klinik IV, Universitaetsklinikum Aachen, RWTH Aachen, Germany
    Leuk Lymphoma 46:1819-24. 2005
  10. ncbi request reprint Methylation-specific polymerase chain reaction
    Oliver Galm
    Medizinische Klinik IV, Universitaetsklinikum Aachen, Aachen, Germany
    Methods Mol Med 113:279-91. 2005

Collaborators

Detail Information

Publications20

  1. pmc Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer
    Erik Noetzel
    Molecular Oncology Group, Institute of Pathology, University Hospital of the RWTH Aachen, Aachen, Germany
    BMC Cancer 8:154. 2008
    ....
  2. pmc Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer
    Jason P W Carey
    Department of Biology, Center for Cancer Research and Therapeutics Development, Clark Atlanta University, Atlanta, GA 30314, USA
    BMC Cancer 9:173. 2009
    ..In this study we provide functional evidence that Id4 indeed acts as a tumor suppressor and is part of a cancer associated epigenetic re-programming...
  3. ncbi request reprint DNA methylation changes in multiple myeloma
    O Galm
    Medizinische Klinik IV, Universitaetsklinikum Aachen, 52074 Aachen, Germany
    Leukemia 18:1687-92. 2004
    ..We conclude that aberrant methylation of tumor suppressor genes is a common event in malignant plasma cell disorders and that there is a correlation between methylation patterns and clinical characteristics in MM patients...
  4. ncbi request reprint Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia
    Oliver Galm
    Medizinische Klinik IV, Universitatsklinikum Aachen, Rheinisch Westfälische Technische Hochschule Aachen, Aachen, Germany
    Ann Hematol 84:39-46. 2005
    ..The growing knowledge of the role of epigenetics in the aberrant silencing of cancer-related genes provides a rationale and molecular basis for targeted therapeutic approaches with demethylating agents in AML...
  5. doi request reprint Epigenetic inactivation of secreted Frizzled-related proteins in acute myeloid leukaemia
    E Jost
    Medizinische Klinik IV, Universitaetsklinikum Aachen, RWTH Aachen, Aachen, Germany
    Br J Haematol 142:745-53. 2008
    ....
  6. doi request reprint Epigenetic dysregulation of secreted Frizzled-related proteins in multiple myeloma
    E Jost
    Medizinische Klinik IV, Universitaetsklinikum Aachen, RWTH Aachen, Germany
    Cancer Lett 281:24-31. 2009
    ..Our data indicate that epigenetic silencing of Wnt antagonists is an early event in MM pathogenesis and that SFRP5 hypermethylation may play a role in disease progression...
  7. ncbi request reprint Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders
    E Jost
    Medizinische Klinik IV, Universitaetsklinikum Aachen, RWTH Aachen, Germany
    Leukemia 21:505-10. 2007
    ....
  8. ncbi request reprint Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis
    J Veeck
    Institute of Pathology, University Hospital of the RWTH Aachen, Aachen, Germany
    Oncogene 25:3479-88. 2006
    ..Our results indicate that promoter hypermethylation is the predominant mechanism of SFRP1 gene silencing in human breast cancer and that SFRP1 gene inactivation in breast cancer is associated with unfavourable prognosis...
  9. ncbi request reprint Heart and muscle involvement by extra-medullary myeloid leukemia: a case report and review of the literature
    E Jost
    Medizinische Klinik IV, Universitaetsklinikum Aachen, RWTH Aachen, Germany
    Leuk Lymphoma 46:1819-24. 2005
    ..Pathological and imaging findings are presented and treatment options are discussed...
  10. ncbi request reprint Methylation-specific polymerase chain reaction
    Oliver Galm
    Medizinische Klinik IV, Universitaetsklinikum Aachen, Aachen, Germany
    Methods Mol Med 113:279-91. 2005
    ..It is a rapid and cost-effective method that does not require radioactive reagents and can be used for the analysis of a large number of clinical samples...
  11. ncbi request reprint Cancer epigenetics and methylation
    Manel Esteller
    Science 297:1807-8; discussion 1807-8. 2002
  12. ncbi request reprint Hypermethylation-associated Inactivation of the Cellular Retinol-Binding-Protein 1 Gene in Human Cancer
    Manel Esteller
    The Johns Hopkins Oncology Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cancer Res 62:5902-5. 2002
    ..Epigenetic disruption of CRBP1 is a common event in human cancer that may have important implications for cancer prevention and treatment using retinoids...
  13. ncbi request reprint SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma
    Oliver Galm
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Blood 101:2784-8. 2003
    ..Silencing of the SOCS-1 gene may impair negative regulation of the Jak/STAT pathway and therefore result in greater responsiveness to cytokines, thus supporting survival and expansion of MM cells...
  14. ncbi request reprint The fundamental role of epigenetics in hematopoietic malignancies
    Oliver Galm
    Medizinische Klinik IV, Universitaetsklinikum Aachen, 52074 Aachen, Germany
    Blood Rev 20:1-13. 2006
    ..The ongoing exploration of basic events involved in altered gene transcription patterns and continued clinical investigative studies are helping to develop novel strategies for the diagnosis, prevention, and treatment of human cancer...
  15. pmc Enzymatic regional methylation assay: a novel method to quantify regional CpG methylation density
    Oliver Galm
    Oncology Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Genome Res 12:153-7. 2002
    ..We demonstrate a use of this technique in determining the methylation density of the promoter region of the tumor suppressor gene p15INK4B and changes that occur after treatment with demethylating agents...
  16. ncbi request reprint Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms
    Steven D Gore
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21287, USA
    Cancer Res 66:6361-9. 2006
    ..The promising percentage of major hematologic responses justifies the testing of such combinations in prospective randomized trials...
  17. ncbi request reprint Beyond genetics--the emerging role of epigenetic changes in hematopoietic malignancies
    Oliver Galm
    Medizinische Klinik IV, Universitaetsklinikum Aachen, Aachen, Germany
    Int J Hematol 80:120-7. 2004
    ..The exploration of our growing knowledge about epigenetic aberrations may help develop novel strategies for the diagnosis and treatment of hematopoietic malignancies in the future...
  18. ncbi request reprint EHA scientific workshop report: the role of epigenetics in hematological malignancies
    Edgar Jost
    Medizinische Klinik IV, Universitaetsklinikum Aachen, RWTH Aachen, Aachen, Germany
    Epigenetics 2:71-9. 2007
    ..The aim of this article is to summarize the major topics discussed at the workshop by leading experts in the field and highlight conclusions for future basic, translational and clinical research...
  19. ncbi request reprint Synergism between rViscumin and cisplatin is not dependent on ERCC-1 expression
    Oliver Galm
    Medizinische Klinik IV, Universitatsklinikum Aachen, Pauwelstrasse 30, 52074 Aachen, Germany
    Cancer Lett 187:143-51. 2002
    ..Our study provides evidence that rViscumin is capable of enhancing cytotoxicity of anticancer agents in vitro. This synergism appears to be independent of transcriptional activity of DNA repair relevant genes...
  20. ncbi request reprint Inactivation of the tissue inhibitor of metalloproteinases-2 gene by promoter hypermethylation in lymphoid malignancies
    Oliver Galm
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Baltimore, MD 21231, USA
    Oncogene 24:4799-805. 2005
    ..We conclude that promoter hypermethylation of TIMP-2 is a novel epigenetic event in the pathogenesis of lymphoid malignancies and may contribute to a more aggressive NHL phenotype...